Teriparatide is used to treat osteoporosis in high-risk patients, especially those who cannot tolerate or did not respond to other therapies. It helps build new bone, strengthen bones, and reduce the risk of fractures.

Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates bone formation when given intermittently at low doses. It activates osteoblasts, increases bone mineral density, and strengthens bones. This anabolic effect makes it effective in reducing fracture risk in patients with severe osteoporosis.

Teriparatide is administered by subcutaneous injection. The injection is usually given in the thigh or abdomen using a prefilled pen device. Patients can self-administer the injection after receiving proper training. It is important to inject teriparatide at the same time each day to maintain consistent levels in the body.

Teriparatide is generally well tolerated but can cause side effects such as nausea, dizziness, leg cramps, headache, and injection site reactions. Mild increases in calcium levels may also occur. Rarely, it may cause low blood pressure upon standing or carry a theoretical risk of osteosarcoma based on animal studies, which limits long-term use. Regular monitoring is recommended to ensure safe treatment.

Teriparatide should not be used in people allergic to the drug or those with conditions like Paget’s disease, unexplained high alkaline phosphatase levels, bone cancers, bone metastases, prior bone radiation, hypercalcemia, or in growing children. Caution is needed in patients with kidney problems or a history of kidney stones, as it can increase calcium levels. Due to a potential osteosarcoma risk seen in animals, treatment is limited to a lifetime maximum of two years. Monitoring of calcium, uric acid, and urinary calcium is recommended, and patients should be aware that dizziness or low blood pressure may occur after injection.

Teriparatide represents a significant advancement in the treatment of osteoporosis, particularly for patients at high risk of fractures who do not respond adequately to traditional therapies. As the first anabolic agent approved for osteoporosis, it works uniquely by stimulating bone formation rather than just preventing bone loss. With proper patient selection, careful monitoring, and adherence to the recommended treatment duration, Teriparatide offers an effective and valuable option for improving bone density, reducing fracture risk, and enhancing overall bone health.

Intermittent, low-dose administration of Teriparatide selectively stimulates osteoblast activity without triggering osteoclast-mediated bone resorption. This contrasts with continuous exposure to PTH, which can cause bone breakdown. The pulsatile stimulation enhances bone matrix formation and improves bone microarchitecture.

Animal studies have shown an increased incidence of osteosarcoma with long-term use of Teriparatide. Although this has not been confirmed in humans, regulatory agencies have restricted cumulative use to 24 months per lifetime as a precautionary measure.

Teriparatide is usually not given alongside antiresorptive drugs (e.g., bisphosphonates) during its course, as the anabolic effects may be reduced. However, after completing Teriparatide therapy, transitioning to an antiresorptive agent helps maintain the newly formed bone and preserve bone mineral density gains.

Mild transient hypercalcemia may occur post-injection. It usually resolves on its own but should be monitored, especially in patients with renal impairment or those taking calcium/vitamin D supplements. Reducing supplement intake or spacing it away from Teriparatide injection may help.

Patients should undergo periodic evaluations of serum calcium, uric acid, renal function, and bone mineral density (BMD). Monitoring is essential to detect hypercalcemia or other metabolic imbalances and to assess therapeutic response.

Yes, if not followed by antiresorptive therapy, patients may lose the bone gained during treatment. To sustain benefits, a bisphosphonate or other antiresorptive agent is typically prescribed immediately after completing Teriparatide.

Teriparatide is not recommended for use in children or young adults with open epiphyses, as it may interfere with bone growth. Its use is generally reserved for older adults or those with severe osteoporosis unresponsive to other treatments.